Back to top
more

ADMA Biologics Inc (ADMA)

(Real Time Quote from BATS)

$2.42 USD

2.42
1,099,594

-0.06 (-2.42%)

Updated Feb 25, 2021 11:24 AM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ADMA More Info

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for ADMA Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents NA 27 23 43 15
Receivables NA 3 1 4 1
Notes Receivable NA 0 0 0 0
Inventories NA 53 19 13 5
Other Current Assets NA 3 2 4 0
Total Current Assets NA 86 45 63 22
Net Property & Equipment NA 32 30 30 2
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 7 8 8 0
Deposits & Other Assets NA 3 7 6 0
Total Assets NA 127 89 108 24
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable NA 0 0 0 6
Accounts Payable NA 9 6 6 3
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 4 4 3 2
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 14 10 9 11
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2 2 3 3
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 83 41 40 12
Non-Current Capital Leases NA 1 0 0 0
Other Non-Current Liabilities NA 0 16 15 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 101 69 68 28
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 291 236 191 102
Retained Earnings NA -265 -216 -151 -107
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 26 20 40 -4
Total Liabilities & Shareholder's Equity NA 127 89 108 24
Total Common Equity 0 26 20 40 -4
Shares Outstanding 94.50 59.30 46.30 45.30 12.80
Book Value Per Share 0.00 0.44 0.43 0.89 -0.35

Fiscal Year End for ADMA Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Assets          
Cash & Equivalents NA 60 76 101 27
Receivables NA 6 7 7 3
Notes Receivable NA 0 0 0 0
Inventories NA 70 56 52 53
Other Current Assets NA 4 5 5 3
Total Current Assets NA 140 143 165 86
Net Property & Equipment NA 40 37 35 32
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 6 6 7 7
Deposits & Other Assets NA 2 5 3 3
Total Assets NA 190 192 211 127
Liabilities & Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 8 7 9 9
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 8 6 4 4
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 16 13 14 14
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2 2 2 2
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 97 97 96 83
Non-Current Capital Leases NA 3 3 2 1
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 119 115 114 101
Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 392 381 380 291
Retained Earnings NA -321 -304 -284 -265
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 71 77 96 26
Total Liabilities & Shareholder's Equity NA 190 192 211 127
Total Common Equity 0 71 77 96 26
Shares Outstanding 94.50 89.60 86.30 86.30 59.30
Book Value Per Share 0.00 0.80 0.89 1.12 0.44